Drug Profile
SMaRT Replacement Therapy - Oragenics
Alternative Names: A2JMLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Oragenics Inc
- Class
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Dental caries
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Dental-caries(Prevention) in USA (Topical)
- 03 May 2019 SMaRT Replacement Therapy is still in phase I trials for Dental caries (Prevention) in USA
- 30 Mar 2011 Oragenics initiates enrolment in a phase I trial in Healthy volunteers in USA